644 related articles for article (PubMed ID: 17312309)
21. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
[TBL] [Abstract][Full Text] [Related]
22. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
[TBL] [Abstract][Full Text] [Related]
23. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
24. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
26. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.
Allen MR; Kubek DJ; Burr DB
J Bone Miner Res; 2010 Jan; 25(1):98-105. PubMed ID: 19580463
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
28. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
31. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
Tonyali O; Arslan C; Altundag K
Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
[TBL] [Abstract][Full Text] [Related]
32. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
33. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
[TBL] [Abstract][Full Text] [Related]
34. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
35. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
36. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.
Arrington SA; Damron TA; Mann KA; Allen MJ
J Surg Oncol; 2008 Mar; 97(3):284-90. PubMed ID: 18161868
[TBL] [Abstract][Full Text] [Related]
37. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
38. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
[TBL] [Abstract][Full Text] [Related]
39. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
40. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P
Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
